IBB Leads Biotech ETF Inflows

IBB Leads Biotech ETF Inflows By: Rob Hughes
on 5/21/2013

Investor inflows into exchange traded funds (ETFs) tracking the biotechnology sector have surged as the share prices of biotech companies make a record breaking start to 2013. According to FT.com, the largest vehicle in the sector, the iShares NASDAQ biotechnology fund (IBB), based on the NASDAQ Biotechnology Index (NBI), has registered inflows of $311.5M so far this year, already surpassing the $287.8M it gathered over the whole of 2012.

IBB has risen 32.6 percent this year, outperforming the second largest fund in the sector, State Street’s SPDR S&P biotech ETF, known as XBI, which is up 25.2 per cent. XBI has attracted $40.8m in new inflows in 2013, up from $24.9m over the whole of last year.

Nasdaq® and Nasdaq® are registered trademarks of The Nasdaq Group, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither The Nasdaq Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies or Nasdaq proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

© 2015. The Nasdaq Group, Inc. All Rights Reserved.

Account Sign In